ONE of the most harrowing prospects for patients undergoing cancer therapy is that the disease will spiral out of control if tumours develop resistance to standard treatments.
Discovery of a “renegade” gene that switches from being a cancer killer to a cancer accomplice could explain why this occurs, and generate better therapies. The gene that changes allegiance makes a receptor that sits on the cell surface and binds to a molecule called the CD95 ligand (CD95L). When CD95L binds to the receptor on normal cells, and on cancer cells sensitive to treatment, it tells the cells to self-destruct.
Common…
